2023
DOI: 10.1016/s1473-3099(22)00594-1
|View full text |Cite
|
Sign up to set email alerts
|

Safety and immunogenicity of an Ad26.ZEBOV booster dose in children previously vaccinated with the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen: an open-label, non-randomised, phase 2 trial

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

0
17
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
6
1

Relationship

2
5

Authors

Journals

citations
Cited by 14 publications
(17 citation statements)
references
References 14 publications
0
17
0
Order By: Relevance
“…Studies EBL2002 and EBL3001 administered an Ad26.ZEBOV booster dose at one and two years post-dose 1, respectively, in adults and a rapid and robust anamnestic response was observed in both studies. 10 , 13 Likewise, results from a study in children aged 4–15 years who had received the Ad26.ZEBOV, MVA-BN-Filo regimen >3 years earlier 16 showed that an Ad26.ZEBOV booster vaccination elicits a rapid and robust anamnestic response. An Ad26.ZEBOV booster may be an effective strategy in preventing EVD in previously vaccinated individuals at imminent risk of infection.…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…Studies EBL2002 and EBL3001 administered an Ad26.ZEBOV booster dose at one and two years post-dose 1, respectively, in adults and a rapid and robust anamnestic response was observed in both studies. 10 , 13 Likewise, results from a study in children aged 4–15 years who had received the Ad26.ZEBOV, MVA-BN-Filo regimen >3 years earlier 16 showed that an Ad26.ZEBOV booster vaccination elicits a rapid and robust anamnestic response. An Ad26.ZEBOV booster may be an effective strategy in preventing EVD in previously vaccinated individuals at imminent risk of infection.…”
Section: Discussionmentioning
confidence: 99%
“…An Ad26.ZEBOV booster may be an effective strategy in preventing EVD in previously vaccinated individuals at imminent risk of infection. 16 …”
Section: Discussionmentioning
confidence: 99%
“… 187 IIb Children Sierra Leone (EBOVAC Booster Study) 56-day interval: P/B: Ad26.ZEBOV/MVA-BN-Filo (EBOVAC Salone) 3 years later B: Ad26.ZEBOV ND Late Ad26.ZEBOV induced a rapid and robust increase in EBOV-specific BAbs. 188 I/II Adults Sierra Leone 57-day interval: P/B: Ad26.ZEBOV/MVA-BN-Filo 2 years later B: Ad26.ZEBOV ND BAbs detected in 98% of subjects. Persistent humoral immune responses.…”
Section: Mva and Nyvac Poxvirus Strains As Vaccine Candidates Against...mentioning
confidence: 97%
“… 16 Similarly, in both a pediatric study and an adult study, a booster dose of Ad26.ZEBOV in children who had received the two-dose regimen >3 years earlier and in HIV-positive adults who had received the two-dose regimen ≥4.5 years earlier was well tolerated and induced a rapid and robust immune response. 19 , 20 Thus far, there are no published clinical data on the immunogenicity and safety of an Ad26.ZEBOV booster dose when administered <1 year after the primary vaccine regimen.…”
Section: Introductionmentioning
confidence: 99%